Industrial conglomerate 3M Company is partnering with the Massachusetts Institute of Technology to develop a cheaper, quicker COVID-19 test.
Right now, test results can take anywhere from a few hours to a week. Quest Diagnostics, for instance, said the average turnaround time at its labs is currently seven days.
3M's new test would function more like a pregnancy strip, a rapid paper-based test that could be mass-produced and quickly distributed at the point of care.
"In terms of patient experience, what we're looking to do is create that low-cost, highly-accurate, simple-to-use test that would be accessible to a lot of people," Dr. John Banovetz, chief technology officer for 3M, told Cheddar.
The antigen-based test, which looks at proteins on the virus, would offer a "preliminary view" of a patient's coronavirus status — though ideally, patients would follow up with a doctor, he added.
"Our goal would be a point-of-care test, so maybe it's taken in a doctor's office. Maybe you pick it up at the pharmacy," Banovetz said.
The goal is to start producing tests by the end of summer or early fall. Once manufacturing is rolling, 3M could produce millions of tests per day, according to the company.
As cases surge across the country and many anticipate a second wave in states where the infection rate has dropped off, calls for more testing are growing.
More than 41 million tests have been reported to the CDC, with a 9 percent positivity rate, but the U.S. continues to lag behind other countries by some measures.
In the meantime, the Trump administration is relying on the private sector to meet the demand for tests, putting pressure on companies such as 3M to come up with a solution.
"We're going as quick as we can right now," he said. "Our focus is trying to get that accuracy up and in a way that we know that we can mass-produce it. That's really where 3M can help contribute to this, our ability to be able to commercialize and bring to market new ideas and innovations."
The U.S. Securities and Exchange Commission Monday laid out a proposal that would require businesses to disclose the emissions they produce. Kathleen Rogers, CEO & President at EARTHDAY.ORG, joined Cheddar News to break down the implications of this historic step.
Deepwell Digital Therapeutics is a game development company looking to transform the way we look at video games — this time to improve health outcomes. Its goal is to create software to aid those who deal with conditions such as depression and ADHD. Company co-founder and co-CEO Ryan Douglas and co-founder Kate Edwards joined Cheddar News to talk about the technology is being used to help patients. "From a research perspective, the game industry itself has been well aware for many, many years of the kind of inherent, kind of anecdotal therapeutic value of playing games," said Edwards.
Catching you up on what you Need to Know on Mar 21, 2022, with updates on the Russian invasion in Ukraine, a Boeing 737-800 plane carrying 132 people crashed in China, Canadian Pacific rail workers on strike, another possible COVID surge, and the SEC's new climate rules for businesses.
The Bill Gates-founded Breakthrough Energy company invested $80 million in Verdox Inc. to facilitate efficient, lower-cost technolog to remove carbon from the air and emission sources. CEO of Verdox, Brian Baynes, joined Cheddar News to discuss the investment, how the company's tech works, and where he sees it going. "We anticipate that with technologies like ours, we potentially can get to the scale of about a million tons per year within 5-10 years," he said. "And then ultimately we need to be doing this at the scales of billions of tons per year and ultimately about 10 billion tons per year in the year 2050."
As the Russia's invasion of Ukraine continues, medical experts are worried conditions in active warzones will exacerbate the current pandemic — or even give rise to other contagions. Dr. Daniel Fagbuyi, a war veteran and former Obama administration biodefense appointee, joined Cheddar News to discuss the ongoing danger of COVID-19 on top of the war, as well as the potential for new variants to emerge. "I mean just large volumes of people definitely is a breeding ground. That's the worst case," he said. "Two things don't mix: war-conflict and a virus, a potential pandemic virus."
Medical cannabis company Akanda went public this week in what was the first traditional IPO of the month. Shares jumped about 163% in the stock's first day of trading. The London-based company says it hopes to supply medical cannabis products to wholesalers in international markets. Tej Virk, CEO of Akanda, joins Cheddar News' Closing Bell to discuss.
